Loading…
Mipletamig demonstrated complete remission in a Phase 1b/2 trial.
Aptevo Therapeutics Inc (APVO) announced that its drug candidate, Mipletamig, achieved a 100% remission rate in a Phase 1b/2 trial cohort for acute myeloid leukemia (AML). The trial results indicate that all patients in the cohort experienced complete remission.
The remission rate of 100% was observed in the specific cohort of the Phase 1b/2 trial. Aptevo Therapeutics has 16,837,000 shares in free float and 16,850,500 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.